Get the Stockscreener App
6.42
7.09%
-0.49
Pre-market:
7.07
0.65
+10.12%
Corbus Pharmaceuticals Holdings Inc stock is traded at $6.42, with a volume of 120.75K.
It is down -7.09% in the last 24 hours and down -32.28% over the past month.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
See More
Previous Close:
$6.91
Open:
$6.93
24h Volume:
120.75K
Relative Volume:
0.46
Market Cap:
$78.19M
Revenue:
$1.54M
Net Income/Loss:
$-38.70M
P/E Ratio:
-1.3747
EPS:
-4.67
Net Cash Flow:
$-36.86M
1W Performance:
-7.89%
1M Performance:
-32.28%
6M Performance:
-88.50%
1Y Performance:
-86.36%
1-Day Range:
$6.375
$6.96
1-Week Range:
$6.375
$7.23
52-Week Range:
$6.375
$61.90
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Name
Corbus Pharmaceuticals Holdings Inc
Sector
Industry
Phone
617-963-0103
Address
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
6.42 | 78.19M | 1.54M | -38.70M | -36.86M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-25 | Initiated | William Blair | Outperform |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Initiated | Wedbush | Outperform |
| Jul-22-24 | Resumed | H.C. Wainwright | Buy |
| Jun-26-24 | Initiated | B. Riley Securities | Buy |
| Jun-03-24 | Reiterated | Oppenheimer | Outperform |
| May-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Mar-06-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-08-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-08-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-08-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-08-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-07-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Mar-26-20 | Initiated | Nomura | Buy |
| Apr-05-19 | Initiated | Jefferies | Buy |
| Mar-20-19 | Initiated | Oppenheimer | Outperform |
| Jan-11-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-26-18 | Initiated | H.C. Wainwright | Buy |
| Dec-07-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-18 | Initiated | B. Riley FBR | Buy |
| Jan-19-18 | Initiated | Raymond James | Outperform |
| Dec-14-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-08-17 | Reiterated | Noble Financial | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Mar-30-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-15-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-11-16 | Reiterated | Noble Financial | Buy |
View All
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Latest News
Wedbush Reaffirms Outperform Rating for Corbus Pharmaceuticals (NASDAQ:CRBP) - Defense World
Corbus Pharmaceuticals (NASDAQ:CRBP) Earns “Buy” Rating from HC Wainwright - Defense World
Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
CRBP stock touches 52-week low at $6.53 amid sharp annual decline - Investing.com UK
Jefferies Financial Group Has Lowered Expectations for Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price - Defense World
Dermatomyositis Treatment Market Size Report 2034 | - openPR
Dermatomyositis Drug Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Treatment Market, Prevalence, Medication, Statistics, Therapies, Companies by DelveInsight - The Globe and Mail
2 Top Resilient Stocks to Buy on Trump Tariffs Dialing Into Strength - The Globe and Mail
Corbus Pharmaceuticals Advances in Oncology and Obesity - TipRanks
Corbus Pharmaceuticals: Q4 Earnings Snapshot - mySA
SEC Form 10-K filed by Corbus Pharmaceuticals Holdings Inc. - Quantisnow
Corbus Pharmaceuticals Holdings Inc. (CRBP) reports earnings - Quartz
Corbus Pharmaceuticals Holdings, Inc. SEC 10-K Report - TradingView
Corbus Pharmaceuticals Reports Q4 2024 Financial Results - TipRanks
Corbus Pharmaceuticals' cash runway expected through third-quarter 2027 -March 11, 2025 at 09:33 am EDT - Marketscreener.com
Corbus Pharmaceuticals Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Corbus Pharmaceuticals: Q4 Earnings Snapshot -March 11, 2025 at 08:18 am EDT - Marketscreener.com
Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update - GlobeNewswire
Corbus Earnings: FDA Fast Track Status Powers $149M Cash Runway Through 2027 - StockTitan
Corbus Pharmaceuticals (CRBP) Projected to Post Quarterly Earnings on Tuesday - Defense World
Corbus Pharmaceuticals (NASDAQ:CRBP) Raised to Sell at StockNews.com - Defense World
Corbus Pharmaceuticals Holdings, Inc. to Host Earnings Call - ACCESS Newswire
Brokerages Set Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) PT at $61.38 - Defense World
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock rises Wednesday, still underperforms market - MarketWatch
When (CRBP) Moves Investors should Listen - Stock Traders Daily
CRBP stock touches 52-week low at $7.22 amid sharp yearly decline - Investing.com India
CRBP stock touches 52-week low at $7.22 amid sharp yearly decline By Investing.com - Investing.com South Africa
Corbus Pharmaceuticals (NASDAQ:CRBP) Research Coverage Started at William Blair - Defense World
Corbus Pharmaceuticals (NASDAQ:CRBP) Earns Outperform Rating from Analysts at William Blair - MarketBeat
William Blair Initiates Coverage of Corbus Pharmaceuticals Holdings (CRBP) with Outperform Recommendation - MSN
William Blair Initiates Corbus Pharmaceuticals at Outperform -February 28, 2025 at 07:57 am EST - Marketscreener.com
Corbus presents new cancer drug study at ASCO GU - MSN
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
Can Corbus' Dual Focus on Oncology and Obesity Attract Investor Attention? CEO Set for Conference Circuit - StockTitan
Invalidations Everywhere… Except in Gold - The Globe and Mail
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
How To Trade (CRBP) - Stock Traders Daily
Dermatomyositis Market Analysis 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Prevalence, Treatment Market, Medication, Revenue, Statistics, Therapies, Companies by DelveInsight - The Globe and Mail
CRBP stock touches 52-week low at $7.87 amid market challenges By Investing.com - Investing.com South Africa
CRBP stock touches 52-week low at $7.87 amid market challenges - Investing.com India
Corbus Pharmaceuticals (NASDAQ:CRBP) Given Buy Rating at HC Wainwright - MarketBeat
Corbus Pharmaceuticals (NASDAQ:CRBP) Given “Buy” Rating at HC Wainwright - Defense World
Corbus Pharmaceuticals CEO Yuval Cohen sells shares worth $62,464 By Investing.com - Investing.com Australia
Corbus Pharmaceuticals CEO Yuval Cohen sells shares worth $62,464 - Investing.com India
Corbus Pharmaceuticals CFO Sean Moran sells $24,446 in stock - Investing.com India
Corbus Pharmaceuticals CFO Sean Moran sells $24,446 in stock By Investing.com - Investing.com Nigeria
Corbus Pharmaceuticals Executives Sell Shares to Cover Tax Obligations - TradingView
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
How Are Things Looking For Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) For The Short Term? - Stocks Register
Investors unsure on Corbus data for potential Padcev rival - The Pharma Letter
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):